Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Brigham and Women's Hospital48,262 enrolled

Overview

This cohort study was initiated to predict the findings of CAROLINA trial in a real world setting using electronic claims data from insurance databases with results anticipated prior to the completion of CAROLINA.

The CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) is an ongoing randomized controlled trial (RCT) designed to assess whether linagliptin is non-inferior, and if so, superior compared with glimepiride 1-4 mg once daily with respect to cardiovascular (CV) events in adults with relatively early Type 2 Diabetes at increased risk of CV events and with less than optimized glycaemic control. Given that medications of both classes are currently advocated as second-line therapy after metformin, and since sulfonylureas have been associated with concerns regarding their CV safety, while dipeptidyl peptidase-4 inhibitors have been suggested to exhibit CV benefits in preclinical and mechanistic trials, the results of this trial will provide answers to several clinically relevant questions and have a significant impact on clinical practice. This cohort study was initiated to predict the findings of CAROLINA trial in a real world setting using electronic claims data from insurance databases with results anticipated prior to the completion of CAROLINA. Trial eligibility criteria were adapted in claims data to generate a comparable study cohort (of linagliptin and glimepiride initiators) to that of the trial population. Using 1:1 propensity score-matching was used to control for \>120 baseline characteristics. Patients were followed up for a composite cardiovascular outcome adapted from the primary end-point of the CAROLINA trial.

Study Type

OBSERVATIONAL

Enrollment

48,262

Conditions

Type 2 Diabetes Mellitus

Eligibility

Sex: ALLMin age: 40 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Type 2 diabetes who were new users of Linagliptin or new users of Glimepiride and: \- Had no more than 3 anti-diabetic drugs including index drug * AND at elevated risk of cardiovascular (CV) events according to specific criteria: * Previous vascular disease * Evidence of vascular-related end-organ damage * Age ⩾ 70 years * ⩾ 2 CV risk factors: * Treated hypertension * Smoking * Using any lipid lowering treatment * Age ≥ 40 and ≤ 85 years at treatment initiation Exclusion Criteria: * Patients with Type 1 Diabetes Mellitus * Previous exposure to dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones (TZDs), insulin or sodium glucose co-transporter-2 (SGLT-2s). * Exclude anti-diabetic background therapy if initiated in 2 months prior * Morbid obesity or treatment with anti-obesity drugs 3 months prior to treatment initiation * Severe hyperglycemia * Active liver disease or impaired hepatic function * Any previous bariatric surgery * Coronary artery re-vascularisation ≤ 6 weeks prior to treatment initiation * Prior hospitalization for congestive heart failure * Acute or chronic metabolic acidosis * Hereditary galactose intolerance * Alcohol or drug abuse within the 3 months prior to treatment initiation * Use of oral corticosteroids * Pregnant women * Patients with cancer * Acute coronary syndrome ≤ 6 weeks prior to treatment initiation * Stroke or Transient ischemic attack ≤ 3 months prior to treatment initiation

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Composite Cardiovascular (CV) Outcome

Composite CV Outcome includes Myocardial infarction, Stroke, hospitalization for unstable angina and Death

Time frame: From treatment initiation to end of follow-up, up to 53 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.